Cancer Cell最新文献

筛选
英文 中文
The KRAS mutational spectrum and its clinical implications in pancreatic cancer 胰腺癌 KRAS 基因突变谱及其临床意义
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.001
Luigi Perelli, Giannicola Genovese, Giulio F. Draetta
{"title":"The KRAS mutational spectrum and its clinical implications in pancreatic cancer","authors":"Luigi Perelli, Giannicola Genovese, Giulio F. Draetta","doi":"10.1016/j.ccell.2024.08.001","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.001","url":null,"abstract":"<p>In this issue of <em>Cancer Cell</em>, McIntyre et al. show that specific mutations in the <em>KRAS</em> proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the <em>KRAS</em><sup><em>G12R</em></sup> mutation is enriched in early-stage PDAC, and it is characterized by distinctly activated molecular programs.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"28 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision oncology across the ages: Impact on children, adolescents, and young adults 跨年龄段的精准肿瘤学:对儿童、青少年和年轻人的影响
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.010
Vivek Subbiah, Razelle Kurzrock
{"title":"Precision oncology across the ages: Impact on children, adolescents, and young adults","authors":"Vivek Subbiah, Razelle Kurzrock","doi":"10.1016/j.ccell.2024.08.010","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.010","url":null,"abstract":"<p>Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups. In this commentary, we review the application of precision oncology across different age groups, specifically in children, adolescents, and young adults, and emphasize that precision medicine is age and tissue agnostic.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"50 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors 癌细胞状态:人类肿瘤单细胞 RNA 测序十年的启示
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.005
Itay Tirosh, Mario L. Suva
{"title":"Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors","authors":"Itay Tirosh, Mario L. Suva","doi":"10.1016/j.ccell.2024.08.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.005","url":null,"abstract":"<p>Human tumors are intricate ecosystems composed of diverse genetic clones and malignant cell states that evolve in a complex tumor micro-environment. Single-cell RNA-sequencing (scRNA-seq) provides a compelling strategy to dissect this intricate biology and has enabled a revolution in our ability to understand tumor biology over the last ten years. Here we reflect on this first decade of scRNA-seq in human tumors and highlight some of the powerful insights gleaned from these studies. We first focus on computational approaches for robustly defining cancer cell states and their diversity and highlight some of the most common patterns of gene expression <em>intra</em>-tumor heterogeneity (eITH) observed across cancer types. We then discuss ambiguities in the field in defining and naming such eITH programs. Finally, we highlight critical developments that will facilitate future research and the broader implementation of these technologies in clinical settings.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"41 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer 在局部晚期直肠癌的新辅助化疗中,PD-1 阻断剂是一种很有前景的辅助疗法
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.003
Ashwin Somasundaram, Hanna K. Sanoff
{"title":"PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer","authors":"Ashwin Somasundaram, Hanna K. Sanoff","doi":"10.1016/j.ccell.2024.08.003","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.003","url":null,"abstract":"<p>Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy has demonstrated efficacy in combination with radiation. In this issue, Xiao et al. demonstrate promising efficacy with the addition of PD-1 blockade to neoadjuvant therapy for mismatch-repair proficient rectal cancer.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"7 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer 人类胰腺癌中特定 KRAS 突变体的不同临床结果和生物学特征
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.002
Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth Seier, Gun Ho Jang, Henry Walch, Victoria G. Aveson, David J. Falvo, William B. Fall, Christopher W. Chan, Andrew Wenger, Brett L. Ecker, Alessandra Pulvirenti, Rebecca Gelfer, Maria Paz Zafra, Nikolaus Schultz, Wungki Park, Eileen M. O’Reilly, Rohit Chandwani
{"title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","authors":"Caitlin A. McIntyre, Adrien Grimont, Jiwoon Park, Yinuo Meng, Whitney J. Sisso, Kenneth Seier, Gun Ho Jang, Henry Walch, Victoria G. Aveson, David J. Falvo, William B. Fall, Christopher W. Chan, Andrew Wenger, Brett L. Ecker, Alessandra Pulvirenti, Rebecca Gelfer, Maria Paz Zafra, Nikolaus Schultz, Wungki Park, Eileen M. O’Reilly, Rohit Chandwani","doi":"10.1016/j.ccell.2024.08.002","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.002","url":null,"abstract":"<p><em>KRAS</em> mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC patients undergoing surgical resection and find that <em>KRAS</em><sup><em>G12R</em></sup> mutations are enriched in early-stage (stage I) disease, owing not to smaller tumor size but increased node-negativity. <em>KRAS</em><sup><em>G12R</em></sup> tumors are associated with decreased distant recurrence and improved survival as compared to <em>KRAS</em><sup><em>G12D</em></sup>. To understand the biological underpinnings, we performed spatial profiling of 20 patients and bulk RNA-sequencing of 100 tumors, finding enhanced oncogenic signaling and epithelial-mesenchymal transition (EMT) in <em>KRAS</em><sup><em>G12D</em></sup> and increased nuclear factor κB (NF-κB) signaling in <em>KRAS</em><sup><em>G12R</em></sup> tumors. Orthogonal studies of mouse <em>Kras</em><sup><em>G12R</em></sup> PDAC organoids show decreased migration and improved survival in orthotopic models. <em>KRAS</em> alterations in PDAC are thus associated with distinct presentation, clinical outcomes, and biological behavior, highlighting the prognostic value of mutational analysis and the importance of articulating mutation-specific PDAC biology.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"57 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells 抗-PD-1和抗-CTLA-4疗法联合疗法产生的克隆反应波包括祖细胞耗竭的CD8+T细胞
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-29 DOI: 10.1016/j.ccell.2024.08.007
Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar, Sabrina Solis, Ajeya Nandi, Shaneaka Anderson, Nicholas Han, Sasikanth Manne, Evgeny Kiner, Chirag Sachar, Minke Lucas, Sangeeth George, Patrick K. Yan, Melanie W. Kier, Amy I. Laughlin, Shawn Kothari, Josephine Giles, Divij Mathew, Alexander C. Huang
{"title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells","authors":"Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar, Sabrina Solis, Ajeya Nandi, Shaneaka Anderson, Nicholas Han, Sasikanth Manne, Evgeny Kiner, Chirag Sachar, Minke Lucas, Sangeeth George, Patrick K. Yan, Melanie W. Kier, Amy I. Laughlin, Shawn Kothari, Josephine Giles, Divij Mathew, Alexander C. Huang","doi":"10.1016/j.ccell.2024.08.007","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.08.007","url":null,"abstract":"<p>Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown promising efficacy in melanoma. However, the underlying mechanism in humans remains unclear. Here, we perform paired single-cell RNA and T cell receptor (TCR) sequencing across time in 36 patients with stage IV melanoma treated with anti-PD-1, anti-CTLA-4, or combination therapy. We develop the algorithm <em>Cyclone</em> to track temporal clonal dynamics and underlying cell states. Checkpoint blockade induces waves of clonal T cell responses that peak at distinct time points. Combination therapy results in greater magnitude of clonal responses at 6 and 9 weeks compared to single-agent therapies, including melanoma-specific CD8<sup>+</sup> T cells and exhausted CD8<sup>+</sup> T cell (T<sub>EX</sub>) clones. Focused analyses of T<sub>EX</sub> identify that anti-CTLA-4 induces robust expansion and proliferation of progenitor T<sub>EX</sub>, which synergizes with anti-PD-1 to reinvigorate T<sub>EX</sub> during combination therapy. These next generation immune profiling approaches can guide the selection of drugs, schedule, and dosing for novel combination strategies.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"379 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 长效 mRNA 编码的白细胞介素-2 可恢复 MHC I 类缺陷癌症患者的 CD8+ T 细胞新抗原免疫力
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-12 DOI: 10.1016/j.ccell.2024.07.010
{"title":"Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers","authors":"","doi":"10.1016/j.ccell.2024.07.010","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.07.010","url":null,"abstract":"No Abstract","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"44 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis 产生 CCL19 的成纤维细胞可促进三级淋巴结构的形成,增强结直肠癌肝转移中的抗肿瘤 IgG 反应
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-12 DOI: 10.1016/j.ccell.2024.07.006
{"title":"CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis","authors":"","doi":"10.1016/j.ccell.2024.07.006","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.07.006","url":null,"abstract":"<p>Tertiary lymphoid structures (TLSs) are associated with enhanced immunity in tumors. However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain unclear. Here, we reveal that intra- and peri-tumor mature TLSs (TLS+) are associated with improved clinical outcomes than TLS− tumors. Using single-cell-RNA-sequencing and spatial-enhanced-resolution-omics-sequencing (Stereo-seq), we reveal that TLS+ tumors are enriched with IgG<sup>+</sup> plasma cells (PCs), while TLS− tumors are characterized with IgA<sup>+</sup> PCs. By generating TLS-associated PC-derived monoclonal antibodies <em>in vitro</em>, we show that TLS-PCs secrete tumor-targeting antibodies. As the proof-of-concept, we demonstrate the anti-tumor activities of TLS-PC-mAb6 antibody in humanized mouse model of colorectal cancer. We identify a fibroblast lineage secreting CCL19 that facilitates lymphocyte trafficking to TLSs. CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice. Our data uncover the central role of CCL19<sup>+</sup> fibroblasts in TLS formation, which in turn generates therapeutic antibodies to restrict CRLM.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"83 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer 开发前列腺癌 ERG 基因融合产物的拟肽抑制剂
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-12 DOI: 10.1016/j.ccell.2024.07.009
{"title":"Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer","authors":"","doi":"10.1016/j.ccell.2024.07.009","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.07.009","url":null,"abstract":"No Abstract","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"19 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers 整合血浆和粪便代谢组学发现腺瘤-结直肠癌进展过程中的功能代谢物和早期诊断生物标记物
IF 50.3 1区 医学
Cancer Cell Pub Date : 2024-08-12 DOI: 10.1016/j.ccell.2024.07.005
{"title":"Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers","authors":"","doi":"10.1016/j.ccell.2024.07.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2024.07.005","url":null,"abstract":"<p>Changes in plasma and fecal metabolomes in colorectal cancer (CRC) progression (normal-adenoma-CRC) remain unclear. Here, plasma and fecal samples were collected from four independent cohorts of 1,251 individuals (422 CRC, 399 colorectal adenoma [CRA], and 430 normal controls [NC]). By metabolomic profiling, signature plasma and fecal metabolites with consistent shift across NC, CRA, and CRC are identified, including CRC-enriched oleic acid and CRC-depleted allocholic acid. Oleic acid exhibits pro-tumorigenic effects in CRC cells, patient-derived organoids, and two murine CRC models, whereas allocholic acid has opposing effects. By integrative analysis, we found that oleic acid or allocholic acid directly binds to α-enolase or farnesoid X receptor-1 in CRC cells, respectively, to modulate cancer-associated pathways. Clinically, we establish a panel of 17 plasma metabolites that accurately diagnoses CRC in a discovery and three validation cohorts (AUC = 0.848–0.987). Overall, we characterize metabolite signatures, mechanistic significance, and diagnostic potential of plasma and fecal metabolomes in CRC.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"43 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信